{
  "source": "PA-Med-Nec-Phexxi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2220-7\nProgram Prior Authorization – Medical Necessity\nMedication Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel\nP&T Approval Date 10/2020, 3/2021, 5/2021, 5/2022, 5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nPhexxi (lactic acid, citric acid, and potassium bitartrate) vaginal gel is indicated for the\nprevention of pregnancy in females of reproductive potential for use as an on-demand method\nof contraception. Phexxi is not effective for the prevention of pregnancy when administered\nafter intercourse.\n2. Coverage Criteriaa:\nA. Authorization\n1. Phexxi will be approved based on all of the following criteria:\na. Used for the prevention of pregnancy\n-AND-\nb. Patient is unable to use other methods of contraception due to failure, contraindication,\nintolerance or refusal. Examples include:\n1) Injection (e.g., Depo-Provera)\n2) Oral Contraceptive [e.g., norethindrone (generic Micronor), Yaz]\n3) Transdermal Patch (e.g. Twirla, Xulane)\n4) Vaginal Contraceptive Ring (e.g., Annovera, NuvaRing)\n5) Diaphragm\n6) Sponge (e.g. Today)\n7) Cervical Cap (e.g., FemCap)\n8) Female Condom\n-AND-\nc. History of failure, contraindication, or intolerance to nonoxynol-9 based spermicide\n-AND-\nd. Provider attests they have counseled the patient regarding a higher rate of pregnancy\nprevention with the use of other methods of contraception (e.g., injection, oral\ncontraception, transdermal patch, vaginal ring) compared to Phexxi\n© 2025 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit plan\ncoverage may also impact coverage criteria. Other policies and utilization management programs may\napply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication hist",
    "ement programs may\napply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Phexxi [package insert]. San Diego, CA: Evofem, Inc; June 2023.\nProgram Prior Authorization – Medical Necessity Phexxi\nChange Control\n10/2020 New program.\n3/2021 Modified provider attestation statement.\n5/2021 Modified provider attestation statement.\n5/2022 Annual review. Updated references.\n5/2023 Annual review. Updated methods of contraception to examples a\nmember is unable to use.\n5/2024 Annual review. Updated references.\n5/2025 Annual review. No changes.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}